News & Media

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integra

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Ea

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide

Teva to Present at the Barclays Global Healthcare Conference

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy,

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily